Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs

Documenti analoghi

• Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
  di: Ahmad Ghorab, et al.
  Pubblicazione: (2022-06-01)
• Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
  di: Naseema Gangat, et al.
  Pubblicazione: (2022-06-01)
• Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm
  di: Naseema Gangat, et al.
  Pubblicazione: (2022-12-01)
• Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
  di: Naseema Gangat, et al.
  Pubblicazione: (2023-03-01)
• Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
  di: Nickolas Steinauer, et al.
  Pubblicazione: (2024-03-01)